Article PDF first page preview

First page of Preoperative role of systemic immune indices in the differential diagnosis between chromophobe renal cell carcinoma and oncocytoma

Objective: The aim of this study is to explore the role of systemic immune indices (systemic immune inflammation index and systemic inflammatory response index) in the differential diagnosis between chRCC and oncocytoma. Methods: The medical records of 162 patients diagnosed with chRCC and 90 patients with oncocytoma, who underwent surgery for renal masses between January 2013 and December 2022, were reviewed. Inflammatory indices, including NLR, PLR, MLR, SII, and SIRI, were calculated for both groups. The results were compared to assess the effects of these markers on RCC subtypes. Results: Median age was significantly higher in the oncocytoma group (65 vs. 61 years, p=0.01). Tumor size was larger in the chRCC group (p<0.001). NLR, MLR, PLR, SII, and SIRI values were significantly higher in chRCC (all p<0.001). ROC analysis showed AUC values of 0.688 (NLR), 0.673 (MLR), 0.750 (PLR), 0.720 (SII), and 0.679 (SIRI). The optimal SII cut-off was 460 (AUC: 0.692), and for SIRI, 0.7 (AUC: 0.647), offering the best discriminative performance between chRCC and oncocytoma. Conclusion: Inflammatory indices, particularly PLR, SII, and SIRI, are accessible and cost-effective tools that can aid in the preoperative distinction of chRCC from oncocytoma, potentially guiding treatment planning.

Journal Section:
Research Article
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.